XLON
SBTX
Market cap18mUSD
Oct 09, Last price
5.35GBP
1D
0.19%
1Q
-47.80%
IPO
-63.32%
Name
SkinBioTherapeutics PLC
Chart & performance
P/E
—
P/S
2.99
EPS
—
Div yield, %
—
Shrs. gr., 5y
12.15%
Rev. gr., 5y
%
Revenues
5m
+283.63%
Net income
-696k
L-75.79%
CFO
-1m
L-52.39%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen the skin's natural barrier, offer protection against infections, and promote the repair of damaged skin. AxisBiotix: Focusing on the intricate link between gut health and skin conditions, this technology aims to mitigate the symptoms experienced by individuals with psoriasis. SkinBioTherapeutics serves a wide range of industries, including cosmetic and pharmaceutical skincare, nutritional supplements, and infection control. The company maintains active collaborations with key partners: Croda Plc; the University of Manchester, for the creation of microbiome formulations that bolster the immune system; and Winclove Probiotics B.V., with whom it's developing a unique probiotic blend derived from specific bacterial species known to influence psoriasis pathways. Originally founded in 2015 as Skinbiotix Ltd, the company adopted its current name, SkinBioTherapeutics plc, in December 2016. Its operations are headquartered in Newcastle upon Tyne, United Kingdom.
Key people
Stuart John Ashman
Chief Executive Officer Designate, Executive Director · since 2019
Catherine O'Neill
Chief Executive Officer, Executive Director · since 2017
Stephen Patrick O'Hara
Non-Executive Director · since 2017
Martin Braddock Hunt
Independent Non-Executive Chairman of the Board · since 2017
Catherine Denise Prescott
Non-Executive Independent Director · since 2017
IPO date
Apr 05, 2017
Employees
12
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
THE CORE
BATH LANE
NEWCASTLE HELIX
NEWCASTLE UPON TYNE, NET NE4 5TF
GB
BATH LANE
NEWCASTLE HELIX
NEWCASTLE UPON TYNE, NET NE4 5TF
GB
Previous name
SKINBIOTHERAPEUTICS LTD
Previous name
SKINBIOTIX LTD
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||